



ATTRACT



Advanced Teaching and TRaining for Adoptive Cell Therapy

13 Research Positions In 6 Different Countries Available NOW!!!

11 PhD Studentships or Early Stage Researchers*
2 Experienced Researchers**

* ESR = Researcher must have less than 4 years research experience since receiving the degree award which qualified them to start a PhD

** ER = In possession of Doctoral degree or more than 4 years research experience AND less than 5 years research experience

Research Themes for ATTRACT:

- *Safety of the adoptive cell therapy in experimental models*
- *Interaction of T cells with the Immune System*
- *Homing and Persistence of T cells*
- *New receptors / Targets*
- *The development of GMP systems*
- *Clinical Trial Design/Monitoring*

Training Programme

This project integrates the expertise of 16 organisations. The partners have extensive knowledge for the further development of adoptive cell therapy, including European experts in T cell engineering, leading authorities in basic and tumour immunology and organisations well versed in clinical trials including the presence of 4 industry representatives who have the proven track record in the biomanufacture of clinical products.

Training will include secondments within the ATTRACT consortium, seminars, summer schools and workshops studying research methodologies, immunotherapy basics. In addition courses in more general areas such as scientific writing, IPR, business skills, experimental design, career development, ethics, etc. will be provided.

Principal Investigator	Contact email	Institution	Project
Robert Hawkins	Rhawkins@picr.man.ac.uk	University of Manchester, UK	Coordinator
Dave Gilham	Dgilham@picr.man.ac.uk	University of Manchester, UK	Issues related to production of therapeutic T cells
Zelig Eshhar	Zelig.eshhar@weizmann.ac.il	Weizmann Institute, Israel	Preclinical models for adoptive T cell therapy using engineered tumor specific T cells.
Reno Debets	j.debets@erasmusmc.nl	Erasmus MC, Rotterdam, NL	Novel tumour antigens as targets for receptor-engineered T cells
Claudio Bordignon	Claudio.Bordignon@molmed.com	Molmed, Milan, Italy	Optimising transduction and function of T cells
Ton Schumacher	t.schumacher@nki.nl	NKI, Amsterdam, NL	Isolation and validation of new TCRs for gene therapy of prostate cancer and melanoma
Thomas Blankenstein	tblank@mdc-berlin.de	MDC, Berlin, Germany	improving the safety of gene-modified T cells
Hinrich Abken	hinrich.abken@uk-koeln.de	University of Cologne, Germany	Gene modified T cell subsets for adoptive transfer
Naomi Taylor	naomi.taylor@igmm.cnrs.fr	CNRS, Montpellier, France	Homing and persistence of gene-modified T cells
Fiona Thistlethwaite	fiona.thistlethwaite@christie.nhs.uk	The Christie, Manchester UK	Clinical Trials of Cell Therapy - Clinical qualification required
Hans Stauss	hstauss@medsch.ucl.ac.uk	UCL, London, UK	Isolation and validation of new TCRs for gene therapy of haematological malignancies
Anna Mondino	mondino.anna@hsr.it	San Raffaele, Milan, Italy	Defining the impact of adoptive T cell transplant on immune competence
Paola Allavena	paola.allavena@humanitasresearch.it	Humanitas, Milan, Italy	Optimization of adoptive T cell therapy by chemokine receptor-directed homing to tumor
Alexander Scheffold	alexandersc@miltenyibiotec.de	Miltenyi, Germany	Isolation, expansion and characterisation of T cells for adoptive immunotherapy
Adrian Abbotts ***		GE Healthcare, UK	
Janos Szollosi ***		University of Debrecen, Hungary	
Richard Dennett ***		Eden Biodesign, UK	

*** Will not host Research Fellow, but will host some courses or workshops.

red indicates fellow has been recruited

For more information please contact Nikki Price
NPrice@picr.man.ac.uk or individual institutions listed above.

Please note that eligibility regulations require that researchers can be nationals of any country other than the country of the premises of the host organisation and may not have resided for more than 1 year in the previous 3 years in the host country.